Early Cancer Detection: What's Going on and What's Next

Area of Science:

• Oncology
• Genomics
• Biotechnology

Background:

• Late-stage cancer diagnosis and limited treatment options contribute significantly to cancer morbidity and mortality.
• Blood-based multicancer early detection (MCED) assays are emerging as a promising strategy to improve early cancer diagnosis and patient outcomes.
• Significant methodological, clinical, and implementation challenges currently impede the widespread adoption of MCED technologies.

Purpose of the Study:

• To review the current landscape of MCED technologies, focusing on circulating cell-free DNA and circulating tumor DNA assays.
• To critically evaluate the developmental status, strengths, and limitations of MCED assays compared to traditional single-cancer screening methods.
• To explore the potential of MCED assays in detecting aggressive and pediatric cancers and discuss implementation considerations.

Main Methods:

• Review of current literature on MCED technologies, including circulating cell-free DNA and circulating tumor DNA-based assays.
• Critical evaluation of the strengths and limitations of MCED assays against established single-cancer screening methods.
• Discussion of the role of artificial intelligence, multi-omics profiling, molecular imaging, and risk-adapted paradigms in MCED development.

Main Results:

• MCED assays, particularly those utilizing circulating DNA, show potential for earlier cancer detection but face developmental and implementation hurdles.
• Integrative approaches and AI, especially deep learning, can enhance MCED assay sensitivity, specificity, and predictive performance.
• MCED testing has the potential to impact cancer mortality, quality of life, and healthcare systems, with ongoing validation and regulatory efforts underway.

Conclusions:

• MCED assays represent a significant advancement in cancer screening, offering the potential for earlier diagnosis and improved patient outcomes.
• Addressing methodological, clinical, and implementation barriers, alongside leveraging AI and multi-omics, is crucial for the successful clinical translation of MCED technologies.
• Future development and widespread adoption of MCED testing could revolutionize cancer care by enabling earlier detection, personalized screening, and improved management of aggressive and pediatric malignancies.